Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools
Identifieur interne : 001708 ( Istex/Curation ); précédent : 001707; suivant : 001709Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools
Auteurs : David R. Lynch [États-Unis] ; Jennifer M. Farmer [États-Unis] ; Robert L. Wilson [États-Unis] ; Laura J. Balcer [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
English descriptors
Abstract
Although several neuroprotective agents have been proposed as potential therapies in Friedreich ataxia (FA), clinical trials of their efficacy are limited by a lack of sensitive outcome measures. We assessed whether performance measures (nine‐hole peg test, the timed 25‐foot walk, and low‐contrast letter acuity) provide valid measures of disease status in FA. Scores for each measure correlated significantly with neurologic disability and disease duration. Rank correlations between scores for performance measures were moderate in magnitude, suggesting that the each test captures separate yet related dimensions of neurological function in FA. Linear regression models demonstrated that scores from the nine‐hole peg test and the timed 25‐foot walk (after reciprocal transformation) were predicted by age and triplet repeat length in patients with FA. In addition, comparison of the temporal courses of change for each performance measure demonstrated that scores from the timed 25‐foot walk change early in the course of FA, nine‐hole peg test scores change slowly over the full course of the disorder, and low‐contrast letter acuity scores change in the later stages of the disease. Thus, a composite scale derived from these performance measures may provide the best overall measure for assessing disease progression throughout the illness. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20449
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001708
Links to Exploration step
ISTEX:56C9C7F682A11ADFD80C1BD7B809FC29973612E2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools</title>
<author><name sortKey="Lynch, David R" sort="Lynch, David R" uniqKey="Lynch D" first="David R." last="Lynch">David R. Lynch</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pediatrics, University of Pennsylvania School of Medicine, and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, University of Pennsylvania School of Medicine, and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Farmer, Jennifer M" sort="Farmer, Jennifer M" uniqKey="Farmer J" first="Jennifer M." last="Farmer">Jennifer M. Farmer</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wilson, Robert L" sort="Wilson, Robert L" uniqKey="Wilson R" first="Robert L." last="Wilson">Robert L. Wilson</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balcer, Laura J" sort="Balcer, Laura J" uniqKey="Balcer L" first="Laura J." last="Balcer">Laura J. Balcer</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:56C9C7F682A11ADFD80C1BD7B809FC29973612E2</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20449</idno>
<idno type="url">https://api.istex.fr/document/56C9C7F682A11ADFD80C1BD7B809FC29973612E2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001708</idno>
<idno type="wicri:Area/Istex/Curation">001708</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools</title>
<author><name sortKey="Lynch, David R" sort="Lynch, David R" uniqKey="Lynch D" first="David R." last="Lynch">David R. Lynch</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Pediatrics, University of Pennsylvania School of Medicine, and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, University of Pennsylvania School of Medicine, and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Farmer, Jennifer M" sort="Farmer, Jennifer M" uniqKey="Farmer J" first="Jennifer M." last="Farmer">Jennifer M. Farmer</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wilson, Robert L" sort="Wilson, Robert L" uniqKey="Wilson R" first="Robert L." last="Wilson">Robert L. Wilson</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balcer, Laura J" sort="Balcer, Laura J" uniqKey="Balcer L" first="Laura J." last="Balcer">Laura J. Balcer</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-07">2005-07</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="777">777</biblScope>
<biblScope unit="page" to="782">782</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">56C9C7F682A11ADFD80C1BD7B809FC29973612E2</idno>
<idno type="DOI">10.1002/mds.20449</idno>
<idno type="ArticleID">MDS20449</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>antioxidant</term>
<term>cardiomyopathy</term>
<term>composite measure</term>
<term>diabetes</term>
<term>mitochondrial disease</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although several neuroprotective agents have been proposed as potential therapies in Friedreich ataxia (FA), clinical trials of their efficacy are limited by a lack of sensitive outcome measures. We assessed whether performance measures (nine‐hole peg test, the timed 25‐foot walk, and low‐contrast letter acuity) provide valid measures of disease status in FA. Scores for each measure correlated significantly with neurologic disability and disease duration. Rank correlations between scores for performance measures were moderate in magnitude, suggesting that the each test captures separate yet related dimensions of neurological function in FA. Linear regression models demonstrated that scores from the nine‐hole peg test and the timed 25‐foot walk (after reciprocal transformation) were predicted by age and triplet repeat length in patients with FA. In addition, comparison of the temporal courses of change for each performance measure demonstrated that scores from the timed 25‐foot walk change early in the course of FA, nine‐hole peg test scores change slowly over the full course of the disorder, and low‐contrast letter acuity scores change in the later stages of the disease. Thus, a composite scale derived from these performance measures may provide the best overall measure for assessing disease progression throughout the illness. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001708 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001708 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:56C9C7F682A11ADFD80C1BD7B809FC29973612E2 |texte= Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |